Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Double-Blind Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cirrhosis (Long-Term Safety)
2011-004728-36Phase 3Terminated
- Sponsor
- Intercept Pharmaceuticals
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary biliary cholangitis (PBC) and Hepatobiliary disorders comparing Obeticholic acid with Placebo (2 arms). Primary endpoint: Primary Endpoint Responder Analysis. Started Feb 2012; status: terminated.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)Hepatobiliary disorders
Beyond the preview
Go deeper on 2011-004728-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004728-36.